Alto Neuroscience, Inc. $ANRO Stake Lifted by Profund Advisors LLC

Profund Advisors LLC lifted its stake in Alto Neuroscience, Inc. (NYSE:ANRO) by 379.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,885 shares of the company’s stock after buying an additional 29,977 shares during the period. Profund Advisors LLC owned approximately 0.10% of Alto Neuroscience worth $967,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ANRO. Sterling Capital Management LLC boosted its stake in Alto Neuroscience by 1,045.7% in the third quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock valued at $27,000 after acquiring an additional 962 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Alto Neuroscience by 48,581.8% during the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock worth $137,000 after purchasing an additional 5,344 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Alto Neuroscience by 18.6% during the second quarter. Wellington Management Group LLP now owns 70,913 shares of the company’s stock worth $1,871,000 after purchasing an additional 11,114 shares in the last quarter. AWM Investment Company Inc. acquired a new stake in shares of Alto Neuroscience during the second quarter worth about $2,111,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Alto Neuroscience in the 2nd quarter valued at about $2,014,000.

Alto Neuroscience Stock Up 2.4%

Shares of Alto Neuroscience stock opened at $22.72 on Wednesday. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. The company’s 50-day simple moving average is $27.77 and its 200-day simple moving average is $24.22. Alto Neuroscience, Inc. has a 52-week low of $10.20 and a 52-week high of $37.48.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08. Analysts predict that Alto Neuroscience, Inc. will post -2.69 earnings per share for the current year.

Insider Activity

In other news, CFO Nicholas Smith sold 24,056 shares of the stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the sale, the chief financial officer directly owned 24,060 shares in the company, valued at $621,229.20. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.25% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wedbush raised their price target on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. HC Wainwright increased their price objective on Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Monday, October 19th. Finally, Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.88.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and central nervous system disorders. The company combines neuroscience research, clinical data and biomarker-based approaches to identify patients who may be more likely to respond to specific treatments.

Alto Neuroscience’s investigational pipeline includes therapies intended to address conditions such as major depressive disorder, bipolar depression, schizophrenia and associated cognitive impairment.